XT
CHRS icon

XTX Topco’s Coherus Oncology CHRS Stock Holding History

XTX Topco’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Buy
123,497
+53,688
+77% +$87.7K ﹤0.01% 3320
2026
Q1 		$118K Sell
69,809
-96,988
-58% -$172K ﹤0.01% 3053
2025
Q4 		$237K Buy
166,797
+69,621
+72% +$101K 0.01% 2270
2025
Q3 		$159K Buy
97,176
+5,437
+6% +$6.05K 0.01% 1919
2025
Q2 		$67.1K Buy
91,739
+36,257
+65% +$31.3K ﹤0.01% 1963
2025
Q1 		$44.8K Buy
55,482
+8,039
+17% +$9.25K ﹤0.01% 2013
2024
Q4 		$65.5K Sell
47,443
-426,074
-90% -$478K 0.01% 1852
2024
Q3 		$492K Buy
473,517
+202,084
+74% +$277K 0.04% 830
2024
Q2 		$470K Buy
271,433
+204,391
+305% +$411K 0.04% 689
2024
Q1 		$160K Sell
67,042
-183,675
-73% -$452K 0.02% 1244
2023
Q4 		$835K Buy
250,717
+230,738
+1,155% +$618K 0.18% 56
2023
Q3 		$74.7K Buy
+19,979
New +$92.3K 0.01% 1223
2023
Q1 		– Sell
-48,756
Closed -$386K – 1315
2022
Q4 		$386K Buy
+48,756
New +$375K 0.08% 430

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

XTX Topco's CHRS Position: Q2 2026 in Review

XTX Topco increased its Coherus Oncology (CHRS) stake by 77% in Q2 2026, buying an estimated $87.7K and bringing the position to 123,497 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #3320.

XTX Topco first reported a position in CHRS in Q4 2022 and has held it in 13 quarters since. The position peaked at $835K in Q4 2023. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • XTX Topco held 123,497 shares of Coherus Oncology worth $173K as of Q2 2026.
  • XTX Topco bought 53,688 Coherus Oncology shares in Q2 2026, an estimated $87.7K.
  • Coherus Oncology made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3320 holding.
  • XTX Topco first reported a position in Coherus Oncology in Q4 2022 and has held it in 13 quarters since.
  • XTX Topco's Coherus Oncology position peaked at $835K in Q4 2023.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.